Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Product Quality ‘Wild Card’? Sarepta’s Gene Therapy Manufacturing Process Change Means More Empty Capsids

Executive Summary

SRP-9001 intended for commercialization is not analytically comparable to the product used in earlier clinical studies; FDA CMC reviewer said agency does not mandate the extent of empty or full capsids but, instead, looks at the totality of data to assess safety and efficacy.

You may also be interested in...

How To Show The US FDA You’ll Be Marketing The Same Cell And Gene Therapies You Trialed

With characterization of cell and gene therapies still in its infancy, the FDA shares advice on how to demonstrate comparability between the versions manufactured for clinical trials and the versions to be produced for commercial use. Starting earlier with scalable manufacturing processes helps. Limited additional clinical studies may be needed in some cases.

Sarepta’s Elevidys: Evidence For Micro-Dystrophin Surrogate Endpoint In Young Patients Insufficient, FDA Reviewers Said

Clinical, statistical and clinical pharmacology review teams recommended a complete response letter, concluding exploratory subgroup analyses of data in four and five year-old DMD patients were insufficient; their views were overridden by CBER Director Peter Marks, who granted accelerated approval for the age-restricted subgroup.

Sarepta’s DMD Gene Therapy Helped Across Accelerated Approval Finish Line By CBER’s Peter Marks

FDA clinical, clinical pharmacology and statistical review teams did not recommend approval of Elevidys, but the CBER director concluded that randomized data in a subgroup of patients ages four and five years old were ‘compelling,’ justifying accelerated approval; expansion beyond this age-restricted subgroup will hinge on data from the EMBARK confirmatory trial.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts